Chronic Spontaneous Urticaria Pipeline Expands with 25+ Therapies and 20+ Companies Advancing Next-Generation Treatments by 2026 | DelveInsight

Chronic Spontaneous Urticaria Companies include Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma, among others.
DelveInsight's report titled "Chronic Spontaneous Urticaria Pipeline Insight 2026" offers an extensive evaluation of the development landscape, highlighting more than 20 companies and over 25 investigational therapies currently progressing in the Chronic Spontaneous Urticaria pipeline. The report presents detailed profiles of pipeline candidates, including both clinical-stage and preclinical products. It also evaluates therapies based on product classification, development phase, route of administration, and molecular category, while additionally identifying inactive or discontinued pipeline candidates within this therapeutic area.

Interested in the newest developments within the Chronic Spontaneous Urticaria pipeline? Discover the latest therapies and ongoing studies here @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Highlights from the Chronic Spontaneous Urticaria Pipeline Report

* On January 13, 2026, Novartis Pharmaceuticals conducted a clinical trial aimed at assessing the pharmacokinetics, safety profile, and therapeutic effectiveness of ligelizumab in adolescents aged 12 to under 18 years suffering from chronic spontaneous urticaria (CSU). Participants received ligelizumab as an adjunct therapy alongside approved doses of H1 antihistamines, consistent with established CSU treatment guidelines.
* On January 08, 2026, Blueprint Medicines Corporation launched a global Phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BLU-808, a wild-type KIT inhibitor. The trial includes participants with chronic inducible urticaria (CIndU) in Part A and chronic spontaneous urticaria (CSU) in Part B.
* On January 06, 2026, Evommune Inc. announced a clinical investigation evaluating the efficacy and safety of multiple dosing regimens of EVO756 in adults diagnosed with moderate-to-severe chronic spontaneous urticaria.
* According to DelveInsight, the Chronic Spontaneous Urticaria pipeline landscape is dynamic and expanding, with more than 20 active pharmaceutical and biotechnology companies collectively developing over 25 innovative therapies targeting the condition.
* Major companies advancing therapies for Chronic Spontaneous Urticaria include Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma, among others.
* Prominent investigational therapies in development include EVO756, Barzolvolimab, CMAB007, JYB1904, Omalizumab, CT-P39, LOU064, Ligelizumab, and several other emerging candidates.

Want to explore which pharmaceutical companies are driving innovation in this space? Access the comprehensive pipeline analysis @ Chronic Spontaneous Urticaria Clinical Trials Assessment - @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

The Chronic Spontaneous Urticaria Pipeline Report delivers a comprehensive disease overview, pipeline analysis, and therapeutic evaluation of the most important drug candidates in development. The report also identifies significant unmet medical needs associated with the management and treatment of Chronic Spontaneous Urticaria.

Chronic Spontaneous Urticaria Overview

Chronic Spontaneous Urticaria (CSU) is defined as the occurrence of recurrent hives persisting for six weeks or longer, typically appearing on most days of the week. The condition is characterized by weals (hives) and angioedema, which can develop on virtually any part of the body and are often widely distributed.

CSU diagnosis generally relies on a clinical history of recurring wheals lasting less than 24 hours without identifiable physical triggers for more than six weeks. International treatment guidelines recommend limited diagnostic testing, typically including complete blood counts, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) assessments.

Common therapies used for managing chronic spontaneous urticaria include antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids.

Chronic Spontaneous Urticaria Emerging Drug Profiles

Remibrutinib: Novartis

Remibrutinib (LOU064) is a highly selective oral Bruton's tyrosine kinase (BTK) inhibitor that blocks the BTK signaling pathway, thereby preventing histamine release responsible for symptoms such as itching, hives, and swelling.

Phase II clinical trials demonstrated rapid therapeutic onset and sustained symptom control in patients with moderate-to-severe chronic spontaneous urticaria. Additionally, the therapy showed good tolerability across all tested dose levels, findings that were later supported by results from the Phase III REMIX study.

Beyond CSU, remibrutinib is being investigated for several immune-mediated diseases, including multiple sclerosis, hidradenitis suppurativa, food allergies, and Sjogren's syndrome.

If approved, remibrutinib could serve as a convenient oral treatment option complementing Xolair Registered (omalizumab), which remains the first and only injectable biologic therapy approved for CSU. The drug is currently undergoing regulatory evaluation for the treatment of Chronic Spontaneous Urticaria.

Barzolvolimab: Celldex Therapeutics

Barzolvolimab (CDX-0159), developed by Celldex Therapeutics, is a humanized monoclonal antibody that selectively targets and inhibits KIT receptor tyrosine kinase, a critical regulator of mast cell survival and activation.

By targeting mast cell pathways, barzolvolimab acts as a precision therapy for mast-cell-driven diseases. In Phase II clinical studies, the therapy demonstrated strong clinical efficacy in chronic spontaneous urticaria, delivering rapid and sustained symptom relief, including reductions of up to 24 points in UAS7 scores by week 12.

A substantial proportion of patients achieved complete disease control through week 52. Observed adverse effects were generally mild and reversible, such as temporary hair color changes and transient neutropenia.

Celldex has initiated global Phase III EMBARQ Registered trials in CSU and plans to explore additional indications including chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis.

Given its strong mast cell-depleting mechanism, barzolvolimab has the potential to reshape treatment strategies across multiple allergic and inflammatory diseases.

JYB1904: Jemincare

JYB1904 is an innovative half-life-extended anti-IgE monoclonal antibody developed by Shanghai Jemincare and licensed internationally as RPT904 outside Greater China.

The therapy is engineered to bind circulating IgE and prevent its interaction with the FcRI receptor on immune cells, thereby suppressing allergic responses.

A Phase I single-dose escalation trial in healthy volunteers demonstrated excellent safety outcomes, with all adverse events classified as Grade 1-2. The drug also showed dose-proportional pharmacokinetics and a median half-life more than twice that of omalizumab, along with greater and longer-lasting suppression of free IgE.

Current Phase II trials in China are examining its pharmacokinetic and pharmacodynamic properties in allergic asthma, with topline results expected by late 2025, as well as its efficacy in chronic spontaneous urticaria.

JYB1904 is supported by a global licensing agreement with RAPT Therapeutics, which included a $35 million upfront payment and milestone payments totaling up to $672.5 million.

This therapy has the potential to become a long-acting next-generation alternative to omalizumab for IgE-mediated allergic diseases.

YH35324: Yuhan Corporation

YH35324 is a next-generation long-acting IgE-trap Fc fusion protein developed by Yuhan Corporation. The therapy works by binding and neutralizing circulating IgE through high-affinity interaction with FcRI, preventing activation of mast cells and basophils involved in allergic responses.

Phase I clinical studies involving single and multiple subcutaneous dose escalation in both healthy volunteers and atopic individuals demonstrated a favorable safety profile, with most adverse events being Grade 1 or 2 and no serious safety concerns reported.

The therapy displayed dose-dependent pharmacokinetics and prolonged IgE suppression, outperforming omalizumab particularly among patients with high baseline IgE levels exceeding 700 IU/mL.

Mechanistic analyses further showed that the therapy reduces FcRI expression on mast cells and basophils, while benefiting from FcRn-mediated recycling, enhancing its duration of action.

Ongoing Phase 1b trials are exploring its use in allergic disorders including chronic urticaria and atopic dermatitis, positioning YH35324 as a potential next-generation treatment option for IgE-driven conditions.

If you are monitoring ongoing Chronic Spontaneous Urticaria clinical trials, this press release offers valuable insights into emerging breakthroughs. Explore the latest updates @ Chronic Spontaneous Urticaria Treatment Drugs - @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Insights Provided in the Chronic Spontaneous Urticaria Pipeline Report

* The report delivers comprehensive insights into companies actively developing treatments for Chronic Spontaneous Urticaria, along with the total number of therapeutic candidates each company is advancing.
* It evaluates therapeutic candidates across early-stage, mid-stage, and late-stage development phases for CSU treatment.
* The report highlights companies engaged in targeted drug development, including both active and inactive or discontinued programs.
* Pipeline candidates are assessed based on development stage, administration route, target receptor, therapeutic strategy (monotherapy or combination therapy), mechanism of action, and molecular class.
* It also provides an in-depth evaluation of strategic collaborations, licensing agreements, partnerships between industry and academia, and financing activities, which are shaping the future growth of the Chronic Spontaneous Urticaria market.

Chronic Spontaneous Urticaria Companies

Major companies operating in this therapeutic area include Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma, and several others.

Therapeutic Assessment by Route of Administration

Pipeline drugs for Chronic Spontaneous Urticaria are categorized by route of administration, including:

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Therapeutic Assessment by Molecule Type

CSU pipeline therapies are also classified according to molecular type, including:

* Monoclonal antibodies
* Small molecules
* Peptides

From innovative drug candidates to competitive intelligence insights, the Chronic Spontaneous Urticaria Pipeline Report delivers a comprehensive evaluation of the therapeutic landscape. Explore more details here @ Chronic Spontaneous Urticaria Market Drivers and Barriers, and Future Perspectives - https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Chronic Spontaneous Urticaria Pipeline Report

* Coverage: Global
* Key Companies: Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma, and others.
* Key Therapies: EVO756, Barzolvolimab, CMAB007, JYB1904, Omalizumab, CT-P39, LOU064, Ligelizumab, among others.

Therapeutic Assessment by Product Type:

* Monotherapy
* Combination therapy
* Mono/Combination

Therapeutic Assessment by Clinical Development Stage:

* Discovery
* Preclinical
* Phase I
* Phase II
* Phase III

Stay informed on the evolving treatment landscape and upcoming innovations shaping Chronic Spontaneous Urticaria therapy @ Chronic Spontaneous Urticaria Emerging Drugs and Major Players @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

* Introduction
* Executive Summary
* Chronic Spontaneous Urticaria Overview
* Pipeline Therapeutics
* Therapeutic Evaluation
* DelveInsight's Analytical Perspective
* Late-Stage Products (Phase III)
* Barzolvolimab - Celldex Therapeutics
* Mid-Stage Products (Phase II)
* JYB1904 - Jemincare
* Early-Stage Products (Phase I)
* YH35324 - Yuhan Corporation
* Preclinical and Discovery-Stage Candidates
* Inactive Pipeline Products
* Key Companies
* Key Products
* Unmet Needs in Chronic Spontaneous Urticaria
* Market Drivers and Barriers
* Future Outlook and Conclusion
* Analyst Perspectives
* Appendix
* About Us

About DelveInsight

DelveInsight is a globally recognized healthcare market research and consulting organization that delivers high-quality market intelligence and strategic insights to help businesses make informed decisions. With a team of experienced analysts and deep expertise across the life sciences and healthcare industries, DelveInsight provides tailored research solutions and actionable insights for clients worldwide. Connect with DelveInsight to access accurate, timely, and data-driven intelligence that helps organizations stay ahead in an evolving healthcare landscape.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-spontaneous-urticaria-pipeline-expands-with-25-therapies-and-20-companies-advancing-nextgeneration-treatments-by-2026-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.